European Heart Journal Advance Access originally published online on October 4, 2006
European Heart Journal 2006 27(23):2784-2814; doi:10.1093/eurheartj/ehl282
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis
Basel Institute for Clinical Epidemiology, University Hospital Basel, Hebelstrasse 10, 4031 Basel, Switzerland
Received 28 April 2006; revised 20 July 2006; accepted 11 September 2006; online publish-ahead-of-print 4 October 2006.
* Corresponding author. Tel: +41 61 265 31 00; fax: +41 61 265 31 09. E-mail address: nordmanna{at}uhbs.ch
See page 2737 for the editorial comment on this article (doi:10.1093/eurheartj/ehl378)
Aims To evaluate the effect of drug-eluting vs. bare metal stents for the treatment of coronary artery disease on overall, cardiac, and non-cardiac mortalities.
Methods and results We conducted a systematic literature search to identify all randomized controlled trials comparing sirolimus or paclitaxel-eluting stents with bare metal stents and reporting mortality data after at least 1 year of follow-up. Trial data were reviewed and extracted independently by two investigators in an unblinded standardized manner. Seventeen trials including a total of 8221 patients were analysed. Peto's odds ratios (ORs) for total mortality after 1 (n=8221), 2 (n=4631), 3 (n=4105), and 4 (n=1293) years of follow-up were 0.94 [95% confidence interval (CI) 0.66–1.34], 1.11 (95% CI 0.76–1.61), 1.25 (95% CI 0.91–1.73), and 1.46 (95% CI 0.92–2.31), respectively. Corresponding ORs for non-cardiac mortality were 1.07 (95% CI 0.64–1.80), 1.72 (95% CI 1.01–2.94), 1.45 (95% CI 0.93–2.25), and 1.65 (95% CI 0.89–3.10). There was no difference in OR for cardiac mortality among all trials. In sensitivity analyses, sirolimus- but not paclitaxel-eluting stents were associated with an increase in non-cardiac mortality at 2 and 3 years of follow-up.
Conclusion Drug-eluting stents for the treatment of coronary artery disease do not reduce total mortality when compared with bare metal stents. Preliminary evidence suggests that sirolimus- but not paclitaxel-eluting stents may lead to increased non-cardiac mortality. Long-term follow-up and assessment of cause-specific deaths in patients receiving drug-eluting stents is mandatory to determine the long-term safety of these devices.
Key Words: Drug-eluting stents • Meta-analysis • Coronary artery disease
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire?
- William C. Wijns and Mitchell W. Krucoff
EHJ 2006 27: 2737-2739.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  A. Menozzi, E. Solinas, P. Ortolani, A. Repetto, F. Saia, G. Piovaccari, A. Manari, E. Magagnini, L. Vignali, E. Bonizzoni, et al. Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study Eur. Heart J., June 9, 2009; (2009) ehp224v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Weisz, M. B. Leon, D. R. Holmes Jr, D. J. Kereiakes, J. J. Popma, P. S. Teirstein, S. A. Cohen, H. Wang, D. E. Cutlip, and J. W. Moses Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1488 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Waksman, R. Erbel, C. Di Mario, J. Bartunek, B. de Bruyne, F. R. Eberli, P. Erne, M. Haude, M. Horrigan, C. Ilsley, et al. Early- and Long-Term Intravascular Ultrasound and Angiographic Findings After Bioabsorbable Magnesium Stent Implantation in Human Coronary Arteries J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 312 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Shishehbor, S. J. Filby, A. K. Chhatriwalla, R. D. Christofferson, A. Jain, S. R. Kapadia, A. M. Lincoff, D. L. Bhatt, and S. G. Ellis Impact of Drug-Eluting Versus Bare-Metal Stents on Mortality in Patients With Anemia J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 329 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kaltoft, L. O. Jensen, M. Maeng, H. H. Tilsted, P. Thayssen, M. Bottcher, J. F. Lassen, L. R. Krusell, K. Rasmussen, K. N. Hansen, et al. 2-Year Clinical Outcomes After Implantation of Sirolimus-Eluting, Paclitaxel-Eluting, and Bare-Metal Coronary Stents Results From the WDHR (Western Denmark Heart Registry). J. Am. Coll. Cardiol., February 24, 2009; 53(8): 658 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ryan, W. Linde-Zwirble, L. Engelhart, L. Cooper, and D. J. Cohen Temporal Changes in Coronary Revascularization Procedures, Outcomes, and Costs in the Bare-Metal Stent and Drug-Eluting Stent Eras: Results From the US Medicare Program Circulation, February 24, 2009; 119(7): 952 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Ph. G. Steg, K. A.A. Fox, K. A. Eagle, M. Furman, F. Van de Werf, G. Montalescot, S. G. Goodman, A. Avezum, W. Huang, J. M. Gore, et al. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events Eur. Heart J., February 1, 2009; 30(3): 321 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Venkitachalam, K. E. Kip, F. Selzer, R. L. Wilensky, J. Slater, S. R. Mulukutla, O. C. Marroquin, P. C. Block, D. O. Williams, S. F. Kelsey, et al. Twenty-Year Evolution of Percutaneous Coronary Intervention and Its Impact on Clinical Outcomes: A Report From the National Heart, Lung, and Blood Institute-Sponsored, Multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries Circ Cardiovasc Intervent, February 1, 2009; 2(1): 6 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/writing members:, J. Daemen, M. L. Simoons, W. Wijns, A. Bagust, G. Bos, J. M. Bowen, E. Braunwald, E. Camenzind, B. Chevalier, et al. Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007 Eur. Heart J., January 2, 2009; 30(2): 152 - 161. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bakhshi, M.J. Edirisinghe, A. Darbyshire, Z. Ahmad, and A.M. Seifalian Electrohydrodynamic Jetting Behaviour of Polyhedral Oligomeric Silsesquioxane Nanocomposite J Biomater Appl, January 1, 2009; 23(4): 293 - 309. [Abstract] [PDF]
|
|
|
|
|
|
R. J. Shemin Coronary Artery Bypass Grafting Versus Stenting for Unprotected Left Main Coronary Artery Disease: Where Lies the Body of Proof? Circulation, December 2, 2008; 118(23): 2326 - 2329. [Full Text] [PDF]
|
|
|
|
|
|
D. E. Cutlip Drug-Eluting or Bare-Metal Stents for ST Elevation Myocardial Infarction Can Observational Data Balance the Risk Benefit Equation? Circ Cardiovasc Intervent, December 1, 2008; 1(3): 161 - 163. [Full Text] [PDF]
|
|
|
|
|
|
J. G. Byrne, M. Leacche, D. E. Vaughan, and D. X. Zhao Hybrid Cardiovascular Procedures J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 459 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-W. Park, S.-C. Yun, S.-W. Lee, Y.-H. Kim, C. W. Lee, M.-K. Hong, S.-S. Cheong, J.-J. Kim, S.-W. Park, and S.-J. Park Stent Thrombosis, Clinical Events, and Influence of Prolonged Clopidogrel Use After Placement of Drug-Eluting Stent: Data From an Observational Cohort Study of Drug-Eluting Versus Bare-Metal Stents J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 494 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Malenka, A. V. Kaplan, F. L. Lucas, S. M. Sharp, and J. S. Skinner Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents JAMA, June 25, 2008; 299(24): 2868 - 2876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kelbaek, L. Klovgaard, S. Helqvist, J. F. Lassen, L. R. Krusell, T. Engstrom, H. E. Botker, E. Jorgensen, K. Saunamaki, S. Aljabbari, et al. Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions: 3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) Trial J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2011 - 2016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. V. Anderson Drug-Eluting Stents: Life Insurance With a Better Death Benefit J. Am. Coll. Cardiol., May 27, 2008; 51(21): 2025 - 2027. [Full Text] [PDF]
|
|
|
|
|
|
S. P. Marso Diabetes and Drug-Eluting Stents: What You Get and What You Don't J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 148 - 149. [Full Text] [PDF]
|
|
|
|
|
|
T. L. Pinto Slottow and R. Waksman Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Endeavor Zotarolimus-Eluting Coronary Stent Circulation, March 25, 2008; 117(12): 1603 - 1608. [Full Text] [PDF]
|
|
|
|
|
|
H. Kelbaek, C. J. Terkelsen, S. Helqvist, J. F. Lassen, P. Clemmensen, L. Klovgaard, A. Kaltoft, T. Engstrom, H. E. Botker, K. Saunamaki, et al. Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trial. J. Am. Coll. Cardiol., March 4, 2008; 51(9): 899 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Hoffmann, M-C Morice, J W Moses, P J Fitzgerald, L Mauri, G Breithardt, J Schofer, P W Serruys, H-P Stoll, and M B Leon Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials Heart, March 1, 2008; 94(3): 322 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jeremias and A. Kirtane Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention Ann Intern Med, February 5, 2008; 148(3): 234 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Saia, A. Marzocchi, and A. Branzi Review: The safety of drug-eluting stents Therapeutic Advances in Cardiovascular Disease, February 1, 2008; 2(1): 43 - 52. [Abstract] [PDF]
|
|
|
|
|
|
N Melikian and W Wijns Drug-eluting stents: a critique Heart, February 1, 2008; 94(2): 145 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. O. Stirban and D. Tschoepe Cardiovascular Complications in Diabetes: Targets and interventions Diabetes Care, February 1, 2008; 31(Supplement_2): S215 - S221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Mulukutla, H. A. Vlachos, O. C. Marroquin, F. Selzer, E. M. Holper, J. D. Abbott, W. K. Laskey, D. O. Williams, C. Smith, W. D. Anderson, et al. Impact of Drug-Eluting Stents Among Insulin-Treated Diabetic Patients A Report from the NHLBI Dynamic Registry. J. Am. Coll. Cardiol. Intv., January 1, 2008; 1: 139 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Abbott, M. R. Voss, M. Nakamura, H. A. Cohen, F. Selzer, K. E. Kip, H. A. Vlachos, R. L. Wilensky, and D. O. Williams Unrestricted Use of Drug-Eluting Stents Compared With Bare-Metal Stents in Routine Clinical Practice: Findings From the National Heart, Lung, and Blood Institute Dynamic Registry J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2029 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Thomas Interventional cardiology and the medical devices industry: is there a conflict of interest? Heart, November 1, 2007; 93(11): 1351 - 1352. [Full Text] [PDF]
|
|
|
|
|
|
A. Schomig, A. Dibra, S. Windecker, J. Mehilli, J. Suarez de Lezo, C. Kaiser, S.-J. Park, J.-J. Goy, J.-H. Lee, E. Di Lorenzo, et al. A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1373 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-G. Chassot, A. Delabays, and D. R. Spahn Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction Br. J. Anaesth., September 1, 2007; 99(3): 316 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Daemen and P. W. Serruys Drug-Eluting Stent Update 2007: Part II: Unsettled Issues Circulation, August 21, 2007; 116(8): 961 - 968. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]
|
|
|
|
|
|
L. O. Jensen, M. Maeng, A. Kaltoft, P. Thayssen, H. H. T. Hansen, M. Bottcher, J. F. Lassen, L. R. Krussel, K. Rasmussen, K. N. Hansen, et al. Stent Thrombosis, Myocardial Infarction, and Death After Drug-Eluting and Bare-Metal Stent Coronary Interventions J. Am. Coll. Cardiol., July 31, 2007; 50(5): 463 - 470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vermeersch, P. Agostoni, S. Verheye, P. Van den Heuvel, C. Convens, F. Van den Branden, G. Van Langenhove, and DELAYED RRISC (Death and Events at Long-term follo Increased Late Mortality After Sirolimus-Eluting Stents Versus Bare-Metal Stents in Diseased Saphenous Vein Grafts: Results From the Randomized DELAYED RRISC Trial J. Am. Coll. Cardiol., July 17, 2007; 50(3): 261 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Valgimigli, G. Campo, C. Arcozzi, P. Malagutti, R. Carletti, F. Ferrari, D. Barbieri, G. Parrinello, G. Percoco, and R. Ferrari Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction: Results From the STRATEGY Study J. Am. Coll. Cardiol., July 10, 2007; 50(2): 138 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kaul, P. K. Shah, and G. A. Diamond As Time Goes By: Current Status and Future Directions in the Controversy Over Stenting J. Am. Coll. Cardiol., July 10, 2007; 50(2): 128 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Krucoff, A. Boam, and D. G. Schultz Drug-Eluting Stents "Deliver Heartburn": How Do We Spell Relief Going Forward? Circulation, June 12, 2007; 115(23): 2990 - 2994. [Full Text] [PDF]
|
|
|
|
|
|
G. W. Stone, S. G. Ellis, A. Colombo, K. D. Dawkins, E. Grube, D. E. Cutlip, M. Friedman, D. S. Baim, and J. Koglin Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation Circulation, June 5, 2007; 115(22): 2842 - 2847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Additional articles abstracted in ACP Journal Club Evid. Based Med., June 1, 2007; 12(3): 94 - 94. [Full Text] [PDF]
|
|
|
|
|
|
H. K. Win, A. E. Caldera, K. Maresh, J. Lopez, C. S. Rihal, M. A. Parikh, J. F. Granada, S. Marulkar, D. Nassif, D. J. Cohen, et al. Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents JAMA, May 9, 2007; 297(18): 2001 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Howard-Alpe, J. de Bono, L. Hudsmith, W. P. Orr, P. Foex, and J. W. Sear Coronary artery stents and non-cardiac surgery Br. J. Anaesth., May 1, 2007; 98(5): 560 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Abbate, G. G.L. Biondi-Zoccai, P. Agostoni, M. J. Lipinski, and G. W. Vetrovec Recurrent angina after coronary revascularization: a clinical challenge Eur. Heart J., May 1, 2007; 28(9): 1057 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Scheller, U. Speck, and M. Bohm Prevention of restenosis: is angioplasty the answer? Heart, May 1, 2007; 93(5): 539 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Cutlip, S. Windecker, R. Mehran, A. Boam, D. J. Cohen, G.-A. van Es, P. Gabriel Steg, M.-a. Morel, L. Mauri, P. Vranckx, et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions Circulation, May 1, 2007; 115(17): 2344 - 2351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Aziz, C. Rao, S. S. Panesar, C. Jones, S. Morris, A. Darzi, and T. Athanasiou Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery BMJ, March 24, 2007; 334(7594): 617 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Camenzind, P. G. Steg, and W. Wijns A Cause for Concern Circulation, March 20, 2007; 115(11): 1440 - 1455. [Full Text] [PDF]
|
|
|
|
 |
|
 J. C.J. Sun, J. W. Eikelboom, P. Agostoni, G. M. Sangiorgi, G. G. Biondi-Zoccai, B. Scheller, M. Bohm, and E. Camenzind Treatment of Restenosis with a Paclitaxel-Coated Balloon Catheter N. Engl. J. Med., March 8, 2007; 356(10): 1071 - 1073. [Full Text] [PDF]
|
|
|
|
|
|
C. Spaulding, J. Daemen, E. Boersma, D. E. Cutlip, and P. W. Serruys A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents N. Engl. J. Med., March 8, 2007; 356(10): 989 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Stone, J. W. Moses, S. G. Ellis, J. Schofer, K. D. Dawkins, M.-C. Morice, A. Colombo, E. Schampaert, E. Grube, A. J. Kirtane, et al. Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents N. Engl. J. Med., March 8, 2007; 356(10): 998 - 1008. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kastrati, J. Mehilli, J. Pache, C. Kaiser, M. Valgimigli, H. Kelbaek, M. Menichelli, M. Sabate, M. J. Suttorp, D. Baumgart, et al. Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents N. Engl. J. Med., March 8, 2007; 356(10): 1030 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lagerqvist, S. K. James, U. Stenestrand, J. Lindback, T. Nilsson, L. Wallentin, and the SCAAR Study Group Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden N. Engl. J. Med., March 8, 2007; 356(10): 1009 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mauri, W.-h. Hsieh, J. M. Massaro, K. K.L. Ho, R. D'Agostino, and D. E. Cutlip Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents N. Engl. J. Med., March 8, 2007; 356(10): 1020 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Drug eluting stents don't reduce mortality in the long term compared with bare metal stents BMJ, February 3, 2007; 334(7587): 248 - 248. [Abstract] [Full Text]
|
|
|
|
|
|
A. Daniel, T. Pinter, I. G Horvath, and A. Komocsi Variability in response to clopidogrel: where is the threshold for 'low response'? Eur. Heart J., February 2, 2007; 28(4): 515 - 516. [Full Text] [PDF]
|
|
|
|
|
|
H. Van Brabandt Stent thrombosis: Antiplatelets alone won't do the job BMJ, January 13, 2007; 334(7584): 57 - 57. [Full Text] [PDF]
|
|
|
|
|
|
W. C. Wijns and M. W. Krucoff Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire? Eur. Heart J., December 1, 2006; 27(23): 2737 - 2739. [Full Text] [PDF]
|
|